Inventiva's Stock Rises Following Positive Update on Lanifibranor Trial

Inventiva, a biopharmaceutical company, has announced a positive recommendation from the fifth Data Monitoring Committee (DMC) for its NATiV3 Phase 3 clinical trial. This trial explores the efficacy of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis (MASH). The DMC's recommendation followed an unblinded review of safety data from over 1000 patients, confirming lanifibranor's favorable safety profile.

Lanifibranor, Inventiva's leading product candidate, is designed to induce anti-fibrotic and anti-inflammatory effects. The ongoing trial's continuation without protocol modification underlines lanifibranor's good tolerability, based on patient data with treatment durations exceeding 24 and 72 weeks.

This development pushes Inventiva closer to potentially offering a new therapy for MASH, a chronic liver disease. The trial's positive momentum may also influence future regulatory approvals, including those from the FDA, which has already given lanifibranor Breakthrough Therapy and Fast Track designations.